Innovative Medicine

Innovative Medicine

March 5, 2013

FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Cardiovascular Events in Patients with Acute Coronary Syndrome

Learn more
Innovative Medicine

February 22, 2013

Janssen Files First Regulatory Application for Simeprevir (TMC435) for the Treatment of Genotype 1 Hepatitis C Patients in Japan

Learn more
Innovative Medicine

February 13, 2013

Janssen Healthcare Innovation launches inaugural Innovation Challenge Prize for Dementia in collaboration with the NHS

Learn more
Innovative Medicine

February 12, 2013

Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration

Investigational oncology agent for B-cell malignancies jointly being developed by Janssen and Pharmacyclics

Learn more
Innovative Medicine

February 12, 2013

Follow-up Data Show ZYTIGA® Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy

Learn more
Innovative Medicine

February 5, 2013

XARELTO® to be Studied with Factor Xa Inhibitor Antidote

Janssen and Bayer Announce Clinical Collaboration Agreement with Portola

Learn more
Innovative Medicine

January 11, 2013

ZYTIGA® Approved In The EU For Use In The Treatment Of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy

Learn more
Innovative Medicine

January 10, 2013

FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes

Learn more
Innovative Medicine

December 31, 2012

FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis

Learn more